Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its new cobas® Respiratory flex test, the first to incorporate Roche’s proprietary TAGS (Temperature-Activated Generation of Signal) technology. This…
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), proudly announces the next chapter of its 2024 BOTOX® Cosmetic grant program, focused on empowering women entrepreneurs. This phase introduces crowdfunding campaigns…
The Ministry of Health, Labour and Welfare of Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL injection for IV infusion every four weeks), Eli Lilly and Company’s (NYSE: LLY) treatment…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that it has filed for regulatory approval to launch a Phase 1/2a clinical trial for ARO-INHBE, its investigational RNA interference (RNAi) therapeutic aimed…
a leading precision medicine company utilizing artificial intelligence (AI) to enhance cancer treatment, has announced its expansion into human oncology. Building on its successful work in veterinary oncology, ImpriMed will…
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven biotech company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced that the FDA has granted…
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has released its…
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the appointment of Catherine Owen Adams as its new Chief Executive Officer (CEO), succeeding Steve Davis. Adams will also join the company’s Board…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the World Health Organization (WHO) has included dual-stain cytology testing in its updated cervical cancer prevention guidelines. The Roche CINtec® PLUS Cytology…
Aditxt, Inc. (NASDAQ: ADTX), an innovation-driven company focused on accelerating healthcare advancements, announced today that its majority-owned subsidiary, Pearsanta, Inc., has entered into a Market Development Collaboration Agreement with Evofem…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval…
Ipsen (Euronext: IPN; ADR: IPSEY) has announced that the European Commission has granted conditional approval for Iqirvo® (elafibranor) 80mg tablets. Iqirvo is approved for the treatment of primary biliary cholangitis…